DaVita Inc. (NYSE:DVA – Get Free Report) reached a new 52-week low during trading on Tuesday after Truist Financial lowered their price target on the stock from $140.00 to $128.00. Truist Financial currently has a hold rating on the stock. DaVita traded as low as $111.43 and last traded at $113.19, with a volume of 213842 shares traded. The stock had previously closed at $113.94.
DVA has been the topic of a number of other reports. Zacks Research upgraded shares of DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. TD Cowen cut their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a report on Monday, November 3rd. Bank of America lowered their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday, September 10th. Barclays dropped their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. Finally, Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $145.60.
View Our Latest Stock Analysis on DaVita
Institutional Trading of DaVita
DaVita Stock Performance
The stock has a fifty day simple moving average of $118.24 and a 200-day simple moving average of $129.48. The stock has a market cap of $8.09 billion, a P/E ratio of 11.81, a PEG ratio of 0.70 and a beta of 0.99.
DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. During the same period in the prior year, the company earned $2.59 earnings per share. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.
About DaVita
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Further Reading
- Five stocks we like better than DaVita
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- A U.S. “birthright” claim worth trillions – activated quietly
- This stock gets a 94 out of 100
- BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
